Axonyx Inc (AXYX)

[trade1]

AXYX should be able to find a development partner for Phenserine after the recent finding. The market for Alzheimers is to big to ignore Phenserines potential. I would be disappointed if AXYX only hit $2.00 on a partnership announcement.

"There was a statistically significant increase in glucose metabolism as compared to baseline in the frontal and parietal cortical areas in the brains of Phenserine patients, while the placebo group did not show any significant changes from baseline. These observed changes were highly correlated with the statistically significant improvement in the Digit Symbol test of attention, an ability that resides in the frontal cortex. The accumulation of FDG is a direct measure of the metabolic activity of neurons and is known to change in parallel with neuronal function. Patients with AD have characteristic reductions in FDG measurements of regional brain activity, which are progressive and correlate to dementia severity."